Ocular Therapeutix
OCUL
130 hedge funds and large institutions have $178M invested in Ocular Therapeutix in 2022 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 44 increasing their positions, 36 reducing their positions, and 14 closing their positions.
64% more call options, than puts
Call options by funds: $2.27M | Put options by funds: $1.38M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
50% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 14
22% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 36
6% more funds holding
Funds holding: 123 → 130 (+7)
1% more capital invested
Capital invested by funds: $176M → $178M (+$1.57M)
2.14% less ownership
Funds ownership: 57.71% → 55.57% (-2.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$2.68M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.47M |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$1.53M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.33M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
MSD Partners
New York
|
-$4.09M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.97M |
| 3 |
Renaissance Technologies
New York
|
-$1.85M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1.72M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.67M |
OCUL Hedge Fund Activity: Q3 2022 in Review
130 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q3 2022, worth a combined $178M — up 0.89% from $176M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new OCUL positions and 14 closed out — a net gain of 7 holders — while 44 added to existing stakes and 36 trimmed.
The largest buyer was Marshall Wace, opening a new position worth an estimated $2.68M. The largest seller was MSD Partners, exiting entirely with an estimated $4.09M sold.
- 130 institutional investors held Ocular Therapeutix (OCUL) as of Q3 2022, up from 123 in Q2 2022.
- Funds reported $178M of Ocular Therapeutix stock for Q3 2022, up 0.89% quarter-over-quarter.
- 21 funds opened new Ocular Therapeutix positions in Q3 2022 and 14 closed out, a net change of +7 holders.
- The largest Ocular Therapeutix buyer in Q3 2022 was Marshall Wace, an estimated $2.68M added.
- The largest Ocular Therapeutix seller in Q3 2022 was MSD Partners, an estimated $4.09M sold.
Based on aggregated 13F filings for Q3 2022.